Giant cell tumour of bone (gctb) is one type of giant-cell-rich bone lesion characterized by the presence of numerous multinucleated osteoclast-type giant cells. Giant cells are known to express rankl (receptor activator of nuclear factor κB ligand) and are responsible for the aggressive osteolytic nature of the tumour. No available treatment option is definitively effective in curing this disease, especially in surgically unsalvageable cases. In recent years, several studies of denosumab in patients with advanced or unresectable gctb have shown objective changes in tumour composition, reduced bony destruction, and clinical benefit. Denosumab is a fully human monoclonal antibody that targets and binds with high affinity and specificity to rankl. Several large phase iii studies have shown that denosumab is more effective than bisphosphonates in reducing skeletal morbidity arising from a wide range of tumours and that it can delay bone metastasis. The relevant articles are reviewed here. The controversies related to the future use of denosumab in the treatment of gctb are discussed.




    Polls results
    1

    On a scale of 1 to 10, rate how much this article will change your clinical practice?

    NO change
    BIG change
    90% Article relates to my practice (10/11)
    9% Article does not relate to my practice (1/11)
    0% Undecided (0/11)
    2

    Will this article lead to more cost-effective healthcare?

    72% Yes (8/11)
    18% No (2/11)
    9% Undecided (1/11)
    3

    Was this article biased? (commercial or personal)

    0% Yes (0/11)
    90% No (10/11)
    9% Undecided (1/11)
    4

    What level of evidence do you think this article is?

    9% Level 1 (1/11)
    45% Level 2 (5/11)
    36% Level 3 (4/11)
    9% Level 4 (1/11)
    0% Level 5 (0/11)